

REMARKS


Claims 1, 3, 4, 5, and 6 have been amended. Claim 2 has been cancelled. Claims 7-9 have been newly added. Thus claims 1 and 3-9 are in the application, and stand ready for action on the merits.

Support for the recitation of atomoxetine hydrochloride in claims 6-9 can be found in the specification as originally filed at, for example, page 12, lines 11-14; page 54, lines 30-31; and in Tables 1 and 2 at pages 58-59.

It is respectfully submitted that entry of the amendments submitted herewith introduces no new matter into the application, and such action is respectfully requested.

If the Examiner has any questions, or would like to discuss any matters in connection with the present application, the Examiner is invited to contact the undersigned at (317) 433-4983.

Respectfully submitted,



Charles E. Cohen, Ph.D.
Attorney for Applicants
Registration No. 34,565
Phone: 317-433-4983

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

08 February 2006